Remicade pushes Mitsubishi Tanabe to growth
This article was originally published in Scrip
Continued strong growth for Remicade (infliximab) offset weakness elsewhere in Mitsubishi Tanabe Pharma's (MTP) portfolio in the nine months to December 31st, nudging overall group revenues into positive territory.
You may also be interested in...
First-line lung cancer approval will expand potential market for Takeda's ALK contender but the latecomer is also facing some well-established class competition in the setting.
US venture raises new funds from Asia partners as it builds a direct presence in China to develop its oncology portfolio.
Novartis gene therapy gets insurance coverage at record price although small patient population will limit system costs.